Coya Therapeutics, Inc. (COYA) Stock

About Coya Therapeutics, Inc.

Coya Therapeutics, Inc. is led by CEO Arun Swaminathan, employs 8 people, headquartered in US, publicly traded since 2022.

Coya Therapeutics, Inc. (COYA) stock trades at $3.94 with a market capitalization of $92.42M. The stock is valued at a negative price-to-earnings (P/E) ratio of -4.53, reflecting a net loss over the last twelve months, price-to-book of 2.65, price-to-sales of 14.19. Over the past 52 weeks the stock has ranged between $3.71 and $7.75, and currently trades 49.2% below its 52-week high.

On profitability, Coya Therapeutics, Inc. generates a return on equity (ROE) of -0.20% (negative, reflecting a net loss), return on capital employed of -0.05%, an operating margin of -2.77%, a net profit margin of -270.22%.

Coya Therapeutics, Inc. by the numbers, 2020–2025

Between 2020 and 2025 Coya Therapeutics, Inc. reported revenue of $0 rising to $8.0M. Compounded, revenue has grown —% a year over five years, —% over three, 100.0% over the last twelve months. Net profit fell to $-21.0M.

The most recent net margin is -270.22%. On a trailing twelve-month basis to Jun '26, revenue is $8.0M and net profit $-22.0M.

Borrowings stand at $0, cash from operations was $-11.0M in the latest year, positive in 0 of the last 6.

Return on equity has averaged -16.7% over five years, and was -48.8% in the most recent year.

The share price itself has compounded at —% a year over five years, -1.6% over three, -14.9% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Coya Therapeutics, Inc. (COYA) — frequently asked questions